Korro Bio, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Korro Bio, Inc. now
Current reporting with the operating signal separated from the noise.
Korro Bio, Inc. (KRRO) upgraded to buy: What does it mean for the stock?
Investors are testing whether Korro Bio, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength?
The story matters when it changes Korro Bio, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Korro Bio, Inc. Announces FDA Orphan Drug Designation for KRRO-110 in Alpha-1 Antitrypsin Deficiency Treatment
The story matters when it changes Korro Bio, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest KRRO filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Korro Bio, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →